NCT02184416 2026-02-27
ADONIS
Pfizer
Completed
Clinical Trials
45 trialsNCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
NCT01552434 2025-10-14
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01210482 2024-09-25
Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Pfizer
Completed
NCT01517243 2023-09-21
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT01174199 2022-10-03
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Terminated
NCT00112840 2022-02-01
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT01392183 2021-09-20
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01827943 2021-05-06
VESTOR
Institut Bergonié
Phase 2 Completed
NCT03571438 2020-01-18
COMBOREIN
University Hospital, Grenoble
Phase NA Unknown
NCT01083368 2019-08-21
Temsirolimus and Bevacizumab in Hormone-Resistant Metastatic Prostate Cancer That Did Not Respond to Chemotherapy
Case Comprehensive Cancer Center
Phase 1/2 Completed
NCT01026623 2019-06-17
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT00378703 2018-11-14
Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT02560012 2018-10-12
Personalized Targeted Inhibitors Treatment in Renal Cell Cancer
The University of Texas Health Science Center, Houston
Phase 2 Terminated
NCT02423954 2018-07-02
NivoPlus
Western Regional Medical Center
Phase 1/2 Terminated
NCT01090466 2018-02-06
Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium
Cardiff University
Phase 1/2 Completed
NCT00782275 2018-01-24
Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01264341 2017-02-14
Efficacy and Safety of Bevacizumab/Temsirolimus Combination to Treat Advanced Renal Cell Carcinoma
Hellenic Cooperative Oncology Group
Phase 2 Terminated
NCT01404104 2016-07-27
Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma
St. Joseph's Healthcare Hamilton
Phase NA Completed
NCT01155258 2016-06-13
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00631371 2016-04-27
INTORACT
Pfizer
Phase 3 Completed
NCT01367457 2016-04-27
INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus
Pfizer
Completed
NCT01206036 2016-01-27
CEPTAS
Central European Society for Anticancer Drug Research
Phase 1/2 Completed
NCT01122615 2015-11-18
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01548482 2015-10-06
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT01020305 2014-10-13
Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer
Stanford University
Phase 1/2 Terminated
NCT00919035 2014-06-30
Single Agent Temsirolimus (Torisel®) in Chemotherapy-naïve Castration-Resistant Prostate Cancer Patients
Oncology Specialists, S.C.
Phase 2 Completed
NCT01198184 2014-05-30
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00887640 2014-02-26
Impact of Temsirolimus Therapy on Circulating Tumor Cell Biology In Men With Castration Resistant Metastatic Prostate Cancer
Duke University
Phase 2 Terminated
NCT00474786 2013-11-21
INTORSECT
Pfizer
Phase 3 Completed
NCT01079286 2013-07-15
I-NET
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 1 Completed
NCT00012142 2013-06-24
CCI-779 in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00045370 2013-06-05
Chemotherapy and Biological Therapy in Treating Patients With Locally Advanced or Metastatic Kidney Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00659568 2013-05-30
Metformin and Temsirolimus in Treating Patients With Metastatic or Unresectable Solid Tumor or Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00112476 2013-05-03
Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01781442 2013-05-01
A Post Marketing Surveillance As Required By Philippine Food And Drug Administration
Pfizer
Withdrawn
NCT00619268 2013-02-15
TORAVA
Centre Leon Berard
Phase 2 Completed
NCT00071968 2013-01-08
Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00512668 2013-01-07
Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00065468 2012-10-25
ARCC
Pfizer
Phase 3 Completed
NCT00979966 2012-07-10
Study in Non-Clear Cell Renal Carcinoma (Ncc-RCC) Temsirolimus Versus Sunitinib
Central European Society for Anticancer Drug Research
Phase 2 Completed
NCT01246817 2012-04-11
Temsirolimus-RCC-imaging
Radboud University Medical Center
Phase 2 Unknown
NCT00563147 2011-10-04
A Phase 1b, Open-Label, Dose-Finding Study to Evaluate the Safety of Tivozanib (AV-951) in Combination With Temsirolimus in Subjects With Metastatic Renal Cell Carcinoma
AVEO Pharmaceuticals, Inc.
Phase 1 Completed
NCT00235794 2007-12-27
An Open Label Exploratory Study in Newly Diagnosed Prostate Cancer Patients
Wyeth is now a wholly owned subsidiary of Pfizer
Phase NA Completed